Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:05:15.758Z.
Consensus retrieved: 2026-10-06T15:58:06.856Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:05:15.758Z.
Quote observation: 2026-10-06T18:00:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c
Forward PE Ratio (N/A) = Dated Quote Price ($1.43) / Consensus Forward EPS ($-0.26)
FORWARD PE RATIO
N/A
RenovoRx, Inc.
Market Cap
$64.43M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| RenovoRx, Inc. (RNXT) | $64.43M | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.41M | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.92M | N/A |
| Alps Group Inc (ALPS)vs › | $63.25M | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | N/A |
| InterCure Ltd. (INCR)vs › | $63.14M | N/A |
| Cingulate Inc. (CING)vs › | $66.20M | N/A |
| XBiotech Inc. (XBIT)vs › | $66.31M | N/A |
| iBio, Inc. (IBIO)vs › | $67.20M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $61.54M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.43, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.26 | $-0.30 – $-0.23 | 2 | n/m |
| 2027-12-31 | $-0.14 | $-0.23 – $-0.05 | 2 | n/m |
| 2028-12-31 | $0.04 | $-0.10 – $0.13 | 3 | 39.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
